ClinicalTrials.gg
CompletedNCT04091217Updated Oct 24, 2024Results posted

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

A Phase 2 interventional study of Atezolizumab and Bevacizumab in Melanoma, sponsored by Hoffmann-La Roche. Completed at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing atezolizumab in Melanoma — 3 open to participants now, 7 under way, 1 of them phase 3. atezolizumab · Melanoma.

Enrollment
12th of 17
43 · median 67
Started
2019
with 1 other
Phase 2
9 of 17
1 open now
Registered
11th of 17
by date
Lead sponsor
5 of 17
Hoffmann-La Roche

Among the 17 studies testing atezolizumab in Melanoma, this one is the 12th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 11th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 17 studies testing atezolizumab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing atezolizumab in Melanoma, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.

Read the detailed description

The study is divided into 2 stages. Stage I of the study is completed when 22 patients with measurable disease have been enrolled and completed ORR evaluation. If the number of responders in Stage I is more than 3, another 16 patients may be enrolled to Stage II.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed unresectable locally advanced(stage III) or (Stage IV) mucosal melanoma
  • May have received prior systemic treatment or treatment naive at enrollment
  • per v1.1
  • Performance Status of 0-1
  • >= 12 weeks
  • Adequate hematologic and end-organ function
  • Negative test at screening
  • Negative surface antigen test at screening
  • Negative hepatitis B core antibody at screening, or positive total HBcAb test followed by quantitative hepatitis B virus DNA\<500 IU/mL at screening.
  • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, and agreement to refrain from donating eggs
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Symptomatic or actively progressing central nervous system (CNS)
  • History of
  • Uncontrolled tumor-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Uncontrolled or symptomatic hypercalcemia
  • Active or history of disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions: 1) Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study. 2) Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. 3) Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible for the study provided all of following conditions are met: (i) Rash must cover \< 10% of body surface area (ii) Disease is well controlled at baseline and requires only low-potency topical (iii) No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Active tuberculosis
  • Significant cardiovascular disease (such as Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • History of other than melanoma within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer
  • Prior allogeneic stem cell or solid organ transplantation
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
  • Current treatment with anti-viral therapy for
  • Current, recent (within 28 days prior to initiation of study treatment) or planned treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intent
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab, 6 months after the final dose of bevacizumab
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Atezolizumab + Bevacizumab

    Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • Atezolizumab 1200 mg will be administered intravenously every 3 weeks.

    Also known as: Tecentriq

  • Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in the Full Analysis Set Analysis Population

    ORR was defined as the percentage of participants with a complete response (CR) defined as disappearance of all target lesions, or partial response (PR) defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR, on two consecutive occasions \>= 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).

    Time frame: Up to approximately 32 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from the date of first treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.

    Time frame: Up to approximately 32 months

  2. Overall Survival (OS)

    Overall survival was defined as the time from the date of first treatment to death from any cause.

    Time frame: Up to approximately 32 months

  3. Duration of Objective Response (DOR)

    DOR was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1

    Time frame: Up to approximately 32 months

  4. Disease Control Rate (DCR)

    DCR was defined as the sum of a complete or partial response or stable disease rates as determined by the investigator according to RECIST v1.1.

    Time frame: Up to approximately 32 months

  5. Percentage of Participants With Adverse Events

    The percentage of participants who experienced an Adverse Event (AE) or Serious Adverse Event (SAE). Incidence, nature, and severity of Adverse Events (AE), are reported per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).

    Time frame: From the first study drug to the data cutoff date: 31 August 2022 (up to approximately 32 months)

07

Results

Posted Oct 24, 2024

Participant flow

This study was conducted at 3 centers in China.

Participant flow — Overall Study
MilestoneAtezolizumab + Bevacizumab
Started43
Stage i analysis population22
Stage ii analysis population38
Completed41
Not completed2
Withdrew: Lost to follow-up2

Outcome measures

SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the date of first treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.

Time frame:
Up to approximately 32 months
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsAtezolizumab + Bevacizumab
Progression-Free Survival (PFS)8.21 (4.07 to 9.59)
SecondaryOverall Survival (OS)

Overall survival was defined as the time from the date of first treatment to death from any cause.

Time frame:
Up to approximately 32 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsAtezolizumab + Bevacizumab
Overall Survival (OS)24.77 (14.88 to NA)
SecondaryDuration of Objective Response (DOR)

DOR was defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1

Time frame:
Up to approximately 32 months
Reported as:
Median · Months
Duration of Objective Response (DOR)
MonthsAtezolizumab + Bevacizumab
Duration of Objective Response (DOR)12.42 (5.59 to 14.03)
SecondaryDisease Control Rate (DCR)

DCR was defined as the sum of a complete or partial response or stable disease rates as determined by the investigator according to RECIST v1.1.

Time frame:
Up to approximately 32 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsAtezolizumab + Bevacizumab
Disease Control Rate (DCR)65.0 (48.32 to 79.37)
SecondaryPercentage of Participants With Adverse Events

The percentage of participants who experienced an Adverse Event (AE) or Serious Adverse Event (SAE). Incidence, nature, and severity of Adverse Events (AE), are reported per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).

Time frame:
From the first study drug to the data cutoff date: 31 August 2022 (up to approximately 32 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events
Percentage of participantsAtezolizumab + Bevacizumab
Percentage of participants with at least 1 AE95.3
Percentage of participants with at least one Grade 3-5 AE25.6
Percentage of participants with at least one AE by worst grade - Grade 141.9
Percentage of participants with at least one AE by worst grade - Grade 227.9
Percentage of participants with at least one AE by worst grade - Grade 323.3
Percentage of participants with at least one AE by worst grade - Grade 40
Percentage of participants with at least one AE by worst grade - Grade 52.3
Percentage with at least one SAE20.9
PrimaryObjective Response Rate (ORR) in the Full Analysis Set Analysis Population

ORR was defined as the percentage of participants with a complete response (CR) defined as disappearance of all target lesions, or partial response (PR) defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR, on two consecutive occasions \>= 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).

Time frame:
Up to approximately 32 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) in the Full Analysis Set Analysis Population
Percentage of participantsAtezolizumab + Bevacizumab
Objective Response Rate (ORR) in the Full Analysis Set Analysis Population45.0 (29.26 to 61.51)

Adverse events

Collected over From the first study drug to the data cutoff date: 31 August 2022 (up to approximately 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atezolizumab + Bevacizumab20/43 (46.5%)9/43 (20.9%)34/43 (79.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventAtezolizumab + Bevacizumab
Immune-mediated hepatitisHepatobiliary disorders2/43
HypophysitisEndocrine disorders2/43
Drug-induced liver injuryHepatobiliary disorders1/43
Abdominal infectionInfections and infestations1/43
AppendicitisInfections and infestations1/43
BronchitisInfections and infestations1/43
Orbital infectionInfections and infestations1/43
EpilepsyNervous system disorders1/43
Post herpetic neuralgiaNervous system disorders1/43
Gastrointestinal perforationGastrointestinal disorders1/43
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAtezolizumab + Bevacizumab
Blood lactate dehydrogenase increasedInvestigations16/43
Blood cholesterol increasedInvestigations11/43
Aspartate aminotransferase increasedInvestigations10/43
Alanine aminotransferase increasedInvestigations9/43
Blood triglycerides increasedInvestigations9/43
PyrexiaGeneral disorders9/43
Blood bilirubin increasedInvestigations8/43
HypothyroidismEndocrine disorders8/43
Blood creatine phosphokinase increasedInvestigations7/43
Blood uric acid increasedInvestigations7/43

Baseline characteristics

Intention-to-treat population is defined as all enrolled participants regardless of whether they receive any assigned study drug.

Age, Continuous
Age, Continuous(Years)Atezolizumab + Bevacizumab
Median61.0 (33 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Atezolizumab + Bevacizumab
Female22
Male21
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atezolizumab + Bevacizumab
American Indian or Alaska Native0
Asian43
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Beijing Cancer Center; Renal Cancer And Melanoma Department.
    Beijing City, 100142, China
  • Fujian Provincial Cancer Hospital
    Fuzhou City, 350014, China
  • Zhejiang Cancer Hospital
    Zhejiang, 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Aug 2022, 33 months.

Results were first posted in Oct 2024, 2 years 1 month after primary completion.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's 33 months is close to that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2019
First posted
Sep 16, 2019
StartActual
Nov 25, 2019
Primary completionActual
Aug 31, 2022
CompletionActual
Sep 1, 2023
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04091217
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Nov 25, 2019
Primary completion
Aug 31, 2022
Completion
Sep 1, 2023
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion